DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mpqwpd/hospital) has announced the addition of the "Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering.
This report on hospital infection therapeutics studies the current as well as future prospects of the market globally.
Hospital infections are also referred to as healthcare-associated infections (HCAIs), nosocomial infections or hospital-acquired infection (HAIs). HAIs can be defined as those infections that occur in patients when they are admitted to a hospital or any other health-care facility with which they were not suffering from at the time of their admission.
A hospital infection also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. Several antimicrobial drugs have proven their effectiveness in treating a range of hospital infections that are globally prevalent at present. This report comprises of an elaborate executive summary, which includes a market snapshot that provides overall information of various segments and sub-segments that are contained in the report. It also provides an overall information and data analysis of the global hospital infection therapeutics market with respect to market segments based on type of drugs used, major hospital infections and geographic regions.
The market for hospital infection therapeutics is segmented into three major therapeutic drug types, namely, antibacterial, antiviral and antifungal drugs. The hospital infection therapeutics market is also segmented on the basis of major hospital infection types into six major categories, namely hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. The market has been extensively analyzed on the basis of the usefulness, effectiveness and sales revenue of major drug types as well as geographic prevalence of major types of hospital infections.
A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. The report also profiles major players of the hospital infection therapeutics market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments.
Scope of the Report
Hospital Infection Therapeutics Market, by Drug Type
- Antibacterial Drugs
- Antiviral Drugs
- Antifungal Drugs
Hospital Infection Therapeutics Market, by Major Infections
- Hospital-Acquired Pneumonia
- Surgical Site Infections
- Urinary Tract Infections
- Gastrointestinal Disorders
- Bloodstream Infections
- Other Hospital Infections
- Actavis plc
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Cubist Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Pfizer, Inc.
For more information visit http://www.researchandmarkets.com/research/mpqwpd/hospital